We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+38.53%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$524M
AUM Growth
+$84.8M
Cap. Flow
-$21.1M
Cap. Flow %
-4.01%
Top 10 Hldgs %
56.21%
Holding
96
New
14
Increased
18
Reduced
28
Closed
8

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$11.2M
2
DNLI icon
Denali Therapeutics
DNLI
+$8.64M
3
PODD icon
Insulet
PODD
+$8.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.91M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$3.95M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$21M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$16.5M
3
BHVN icon
Biohaven
BHVN
+$7.62M
4
MBX
MBX Biosciences
MBX
+$5.72M
5
KALV
KalVista Pharmaceuticals
KALV
+$5.38M

Sector Composition

Rank Sector Weight
1 Healthcare 92.52%
2 Miscellaneous 7.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
26
Tandem Diabetes Care
TNDM
$1.49B
$5.36M 1.02%
355,208
– –
ALKS icon
27
Alkermes
ALKS
$7.95B
$5.31M 1.01%
101,266
-38,216
-27% -$1.49M
STOK icon
28
Stoke Therapeutics
STOK
$2.04B
$4.28M 0.82%
130,875
– –
ALLO icon
29
Allogene Therapeutics
ALLO
$698M
$4.16M 0.79%
2,000,000
+629,882
+46% +$1.38M
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.51B
$4M 0.76%
400,248
-30,000
-7% -$271K
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.9M 0.74%
130,175
– –
KIDS icon
32
OrthoPediatrics
KIDS
$617M
$3.62M 0.69%
189,130
+93,471
+98% +$1.62M
HELP
33
Cybin Inc
HELP
$890M
$3.4M 0.65%
514,061
+15,700
+3% +$78.5K
RAPP
34
Rapport Therapeutics
RAPP
$2.34B
$3.13M 0.6%
75,000
– –
KYMR icon
35
Kymera Therapeutics
KYMR
$9.82B
$3.1M 0.59%
+27,000
New +$2.32M
PRQR icon
36
ProQR Therapeutics
PRQR
$323M
$2.85M 0.54%
1,530,361
-37,200
-2% -$61.3K
NGNE icon
37
Neurogene
NGNE
$732M
$2.8M 0.53%
89,032
+32,397
+57% +$892K
ANL
38
Adlai Nortye Group ADS
ANL
$890M
$2.75M 0.53%
+239,553
New +$2.91M
PRCT icon
39
Procept Biorobotics
PRCT
$1.19B
$2.71M 0.52%
120,000
– –
AQST icon
40
Aquestive Therapeutics
AQST
$630M
$2.69M 0.51%
645,915
+277,500
+75% +$1.17M
CLDX icon
41
Celldex Therapeutics
CLDX
$3.07B
$2.55M 0.49%
68,518
– –
GPCR icon
42
Structure Therapeutics
GPCR
$3.38B
$2.5M 0.48%
46,500
– –
ALGN icon
43
Align Technology
ALGN
$11.2B
$2.36M 0.45%
14,000
-1,000
-7% -$174K
VKTX icon
44
Viking Therapeutics
VKTX
$3.75B
$2.32M 0.44%
59,516
– –
NGEN
45
NervGen Pharma
NGEN
$245M
$2.16M 0.41%
+1,050,000
New +$3.26M
BHVN icon
46
Biohaven
BHVN
$2.33B
$2.05M 0.39%
137,593
-708,142
-84% -$7.62M
MAZE
47
Maze Therapeutics
MAZE
$1.52B
$1.94M 0.37%
65,000
+30,000
+86% +$786K
ALEC icon
48
Alector
ALEC
$261M
$1.83M 0.35%
908,351
– –
LXEO icon
49
Lexeo Therapeutics
LXEO
$399M
$1.76M 0.33%
377,059
– –
PROF
50
Profound Medical
PROF
$250M
$1.73M 0.33%
260,360
-2,645
-1% -$17.8K
1
2
3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, DAFNA Capital Management held 96 positions worth $524M, up 19% from $440M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

DAFNA Capital Management withdrew a net $21.1M in Q2 2026, closing 8 positions and reducing 28 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in NervGen Pharma worth $2.16M.

  • DAFNA Capital Management's largest Q2 2026 buy was NervGen Pharma: 1,050,000 shares worth $2.16M.
  • DAFNA Capital Management added most to Nektar Therapeutics in Q2 2026, an estimated $11.2M increase.
  • DAFNA Capital Management's biggest Q2 2026 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $16.5M.
  • DAFNA Capital Management fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $21M.
  • DAFNA Capital Management's ten largest holdings make up 56% of its $524M portfolio in Q2 2026.
  • DAFNA Capital Management opened 14 new positions and closed 8 in Q2 2026.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $524M.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.